Based on current safety data, tirzepatide (sold as Zepbound) has the most favorable safety profile among FDA-approved weight loss injections, showing consistently lower rates of serious complications than semaglutide (Wegovy) or liraglutide (Saxenda). That said, no weight loss injection is free of side effects, and the safest choice for any individual depends on their medical history.
Three injectable medications are currently approved for weight management in the U.S.: liraglutide, semaglutide, and tirzepatide. All belong to a class of drugs that mimic gut hormones to reduce appetite and slow digestion. They differ meaningfully in their side effect profiles, how much weight they produce, and what risks they carry over the long term.
How the Three Injections Compare on Safety
Large-scale adverse event analyses paint a clear picture of how these drugs stack up. Tirzepatide shows the lowest signal for serious kidney and pancreatic problems, with reporting rates roughly half of what you’d expect in the general population. Semaglutide falls in the middle, while liraglutide, the oldest of the three, carries the highest rates of pancreatic and kidney-related complications.
The differences are especially stark for acute pancreatitis. Liraglutide’s adverse event signal is roughly three times higher than semaglutide’s and more than 15 times higher than tirzepatide’s. For acute kidney injury, tirzepatide again shows the lowest risk, with a reporting rate about one-third of what’s seen in the background population. Semaglutide sits slightly above baseline, and liraglutide falls roughly in line with expected rates.
Liraglutide also carries a notably higher signal for pancreatic cancer compared to the newer drugs. Around 14% of patients in Saxenda’s clinical trials withdrew from treatment, with adverse events among the top reasons. This higher dropout rate reflects the drug’s less favorable tolerability overall.
Stomach Side Effects: The Most Common Problem
Nausea, vomiting, diarrhea, and constipation are the side effects you’re most likely to experience with any of these injections. They typically peak during the first few weeks or after a dose increase, then taper off as your body adjusts.
In clinical trials, about 31% of people taking semaglutide reported gastrointestinal issues, compared to roughly 13% on placebo. Tirzepatide’s numbers look different depending on how you measure them: aggregate GI event rates reached nearly 80% in some trials, though this higher figure reflects how events were counted across longer study periods and multiple dose levels rather than a dramatically worse experience. In practice, both drugs cause similar day-to-day stomach discomfort for most people, and these symptoms are rarely dangerous. They become a safety concern mainly when severe vomiting or diarrhea leads to dehydration, which can stress the kidneys.
Rare but Serious Risks
All three injections carry a boxed warning about thyroid tumors. In animal studies, these drugs caused thyroid C-cell tumors in rodents. Whether this translates to humans has been harder to pin down. A large Scandinavian study tracking more than 145,000 patients on GLP-1 drugs found thyroid cancer developed at a rate of about 1.3 per 10,000 person-years, which was actually slightly lower than the comparison group. The specific risk of medullary thyroid carcinoma showed no statistically significant increase.
Pancreatitis remains a concern with all three drugs, though the absolute risk is low. Symptoms to watch for include severe abdominal pain that radiates to your back, especially with nausea and vomiting. If you’ve had pancreatitis before, these medications may not be appropriate for you.
Muscle Loss: A Hidden Safety Concern
One safety issue that gets less attention is how much muscle you lose along with fat. Studies show that 25% to 39% of the total weight lost on these medications comes from lean mass rather than fat, measured over 36 to 72 weeks. That’s higher than the 10% to 30% muscle loss seen with standard calorie restriction alone.
To put this in perspective, the annual rate of muscle loss on GLP-1 drugs is several times greater than what normally happens from aging, which averages about 0.8% per year between ages 40 and 70. This matters because losing too much muscle can weaken bones, reduce mobility, and lower your metabolic rate. Resistance training and adequate protein intake during treatment can help offset this loss, and it’s something worth planning for before you start.
Cardiovascular Benefits of Semaglutide
One area where semaglutide has an edge is heart health. The SELECT trial, which followed thousands of patients with pre-existing cardiovascular disease and obesity, found that semaglutide 2.4 mg reduced major cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% compared to placebo. This benefit held up even in patients with heart failure, regardless of the type. No similar large-scale cardiovascular outcome trial has been completed for tirzepatide yet, so if you have established heart disease, semaglutide’s proven cardiac benefit could make it the safer overall choice despite its slightly higher GI and pancreatic risk profile.
Who Should Avoid Weight Loss Injections
Certain medical histories make these drugs unsafe. You should not use any GLP-1 based injection if you have a personal or family history of medullary thyroid cancer, or a genetic condition called multiple endocrine neoplasia type 2 (MEN2). These are rare, but the risk is serious enough to warrant a boxed warning on every product.
Other conditions that require caution or may rule out these medications include severe gastroparesis (a condition where the stomach empties very slowly), a history of pancreatitis, kidney disease, diabetic retinopathy, and mood disorders like depression, since there have been reports of suicidal thoughts in some patients. These drugs have not been studied enough in pregnancy to establish safety, and animal studies suggest a risk of birth defects.
Why Compounded Injections Are the Least Safe Option
If you’ve seen cheaper semaglutide or tirzepatide offered through online clinics or compounding pharmacies, understand that these products carry substantially higher risks. The FDA has received reports of hospitalizations tied to dosing errors with compounded semaglutide, with patients accidentally injecting 5 to 20 times the intended dose from multi-dose vials. Healthcare providers have also miscalculated doses when converting between milligrams and units.
Compounded products don’t go through FDA review for safety, quality, or effectiveness. Some compounders use salt forms of semaglutide (like semaglutide sodium or semaglutide acetate) that are chemically different from the active ingredient in approved drugs. Others add ingredients like vitamin B-12, L-carnitine, or NAD, and the safety of these combinations has never been tested. The price savings simply aren’t worth the risk of an unregulated product with no standardized dosing.
Choosing Based on Your Situation
For most people without cardiovascular disease, tirzepatide (Zepbound) currently has the best safety data. Its rates of serious pancreatic, kidney, and metabolic complications are the lowest of the three approved options, and it produces the most weight loss in head-to-head comparisons. If you have established heart disease, semaglutide (Wegovy) offers a proven 20% reduction in cardiovascular events that no other weight loss injection has matched yet. Liraglutide (Saxenda) is generally considered a third-line option now, given its less favorable safety profile and more modest weight loss results compared to the newer drugs.
Regardless of which injection you use, the safety picture improves when you pair it with strength training to protect muscle mass, stay well-hydrated to protect your kidneys, and use only FDA-approved products at verified doses.